Developments in antithrombotic therapy: state of the art anno 1996: state of the art anno 1996

H. ten Cate; M. T. Nurmohamed; J. W. ten Cate

doi:https://doi.org/10.1007/BF00735960

Developments in antithrombotic therapy: state of the art anno 1996: state of the art anno 1996

H. ten Cate, M. T. Nurmohamed, J. W. ten Cate

Research output: Contribution to journal › Review article › Academic › peer-review

3 Citations (Scopus)

Abstract

This review aims to discuss recent developments in antithrombotic therapy. New and specific inhibitors of platelet dependent thrombosis appear to moderately improve the outcome in coronary vascular disease. Further studies will need to address the cost-benefit ratio of this additional intervention. Hirudin and analogues are potent inhibitors of thrombin, and are clinically efficious, but at current dosage levels still complicated by bleeding. Low molecular weight heparin have markedly improved the efficacy of prevention and treatment of venous thromboembolism

Original language	English
Pages (from-to)	195-203
Number of pages	9
Journal	Pharmacy World & Science
Volume	18
Issue number	6
DOIs	https://doi.org/10.1007/BF00735960
Publication status	Published - Dec 1996

Keywords

Coronary Disease/drug therapy
Fibrinolytic Agents/pharmacology
Humans

Access to Document

https://doi.org/10.1007/BF00735960

Cite this

@article{d2e931b760de4075a631701ba489e17e,

title = "Developments in antithrombotic therapy: state of the art anno 1996: state of the art anno 1996",

abstract = "This review aims to discuss recent developments in antithrombotic therapy. New and specific inhibitors of platelet dependent thrombosis appear to moderately improve the outcome in coronary vascular disease. Further studies will need to address the cost-benefit ratio of this additional intervention. Hirudin and analogues are potent inhibitors of thrombin, and are clinically efficious, but at current dosage levels still complicated by bleeding. Low molecular weight heparin have markedly improved the efficacy of prevention and treatment of venous thromboembolism",

keywords = "Coronary Disease/drug therapy, Fibrinolytic Agents/pharmacology, Humans",

author = "{ten Cate}, H. and Nurmohamed, {M. T.} and {ten Cate}, {J. W.}",

year = "1996",

month = dec,

doi = "https://doi.org/10.1007/BF00735960",

language = "English",

volume = "18",

pages = "195--203",

journal = "Pharmacy World & Science",

issn = "0928-1231",

publisher = "Kluwer Academic Publishers",

number = "6",

}

TY - JOUR

T1 - Developments in antithrombotic therapy: state of the art anno 1996

T2 - state of the art anno 1996

AU - ten Cate, H.

AU - Nurmohamed, M. T.

AU - ten Cate, J. W.

PY - 1996/12

Y1 - 1996/12

N2 - This review aims to discuss recent developments in antithrombotic therapy. New and specific inhibitors of platelet dependent thrombosis appear to moderately improve the outcome in coronary vascular disease. Further studies will need to address the cost-benefit ratio of this additional intervention. Hirudin and analogues are potent inhibitors of thrombin, and are clinically efficious, but at current dosage levels still complicated by bleeding. Low molecular weight heparin have markedly improved the efficacy of prevention and treatment of venous thromboembolism

AB - This review aims to discuss recent developments in antithrombotic therapy. New and specific inhibitors of platelet dependent thrombosis appear to moderately improve the outcome in coronary vascular disease. Further studies will need to address the cost-benefit ratio of this additional intervention. Hirudin and analogues are potent inhibitors of thrombin, and are clinically efficious, but at current dosage levels still complicated by bleeding. Low molecular weight heparin have markedly improved the efficacy of prevention and treatment of venous thromboembolism

KW - Coronary Disease/drug therapy

KW - Fibrinolytic Agents/pharmacology

KW - Humans

U2 - https://doi.org/10.1007/BF00735960

DO - https://doi.org/10.1007/BF00735960

M3 - Review article

C2 - 9010882

SN - 0928-1231

VL - 18

SP - 195

EP - 203

JO - Pharmacy World & Science

JF - Pharmacy World & Science

IS - 6

ER -